4 Dec 2025 • A major trial confirmed that a single dose of human papillomavirus vaccine shielded adolescent girls against high-risk HPV16 and HPV18 as effectively as the standard two-dose regimen.

Among 20,330 participants aged 12–16 receiving bivalent or nonavalent vaccines, rate differences stayed within −0.13 to 0.21 infections per 100, with vaccine effectiveness ≥97% across all groups over five years. No major safety issues were reported.

The results indicate that a one-dose strategy could meaningfully widen global HPV vaccine access, especially in regions where completing multidose schedules remains a barrier.

Source: NEJM | Read Full Story